	US 11,992,495 B2
	Enhancing GABA's ability to modulate immune responses
Daniel Kaufman, Los Angeles, CA (US); and Jide Tian, Los Angeles, CA (US)
Assigned to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Appl. No. 16/625,181
Filed by THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
PCT Filed Jun. 20, 2018, PCT No. PCT/US2018/038428 § 371(c)(1), (2) Date Dec. 20, 2019, PCT Pub. No. WO2018/236955, PCT Pub. Date Dec. 27, 2018.
Claims priority of provisional application 62/524,338, filed on Jun. 23, 2017.
Prior Publication US 2020/0138830 A1, May 7, 2020
Int. Cl. A61K 31/5517 (2006.01); A61K 9/20 (2006.01); A61K 31/5513 (2006.01); A61K 31/57 (2006.01); A61P 29/00 (2006.01); A61P 37/02 (2006.01)

CPC A61K 31/5517 (2013.01) [A61K 9/20 (2013.01); A61K 31/5513 (2013.01); A61K 31/57 (2013.01); A61P 29/00 (2018.01); A61P 37/02 (2018.01)]

15 Claims

1. A method of reducing an inflammatory immune response and/or promoting a regulatory immune response in a mammal, said method comprising administering to said mammal the GABA_Areceptor positive allosteric modulator (PAM) alprazolam and the GABA receptor activating ligand GABA, wherein the dose of GABA would be sufficient to achieve a reduction of an inflammatory immune response and/or promotion of a regulatory immune response when used alone, and the dose of alprazolam is sufficient to increase the reduction of an inflammatory immune response and/or promotion of a regulatory immune response, and wherein the combination of said alprazolam and GABA is more effective to reduce an inflammatory immune response and/or to promote a regulatory immune response in said mammal than when either agent is administered alone.